Olgotrelvir – Mpro/Cathepsin

SARS-CoV-2 Inhibitor is a next generation standalone oral treatment for COVID-19. It is the first clinical stage dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L), which can effectively inhibit both SARS-CoV-2 replication and entry into host cells.

An oral antiviral drug that blocks both SARS-CoV-2 replication in cells, and the virus entry into human cells.